A Phase 3 interventional study of Adalimumab and Upadacitinib in Psoriatic Arthritis, sponsored by AbbVie. Completed at 345 sites in 46 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 21st registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Czechia and 3 more countries
Ages 18+
AbbVie · Sites in Argentina, Austria, Belgium and 12 more countries
Ages 18–75
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
AbbVie · Sites in United States
Women only
By country, each count listing its studies:
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,705 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 246 across the 11 interventional studies, 474 across the 22 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg and 30 mg QD versus placebo for the prevention of structural progression.
The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg and 30 mg QD in participants who have completed Period 1.
The study includes a 35-day screening period, a 56-week blinded period (Period 1), a long-term extension period of up to a total treatment duration of approximately 5 years (Period 2), a 30-day follow-up call or visit, and a 70-day follow-up call.
Period 1 includes 24 weeks of randomized, double-blind, placebo-controlled and active comparator-controlled treatment followed by 32 weeks of active comparator-controlled upadacitinib; at Week 24 participants assigned to placebo will be switched to upadacitinib according to their randomization assignment.
Participants who meet eligibility criteria will be randomized in a 2:2:2:1:1 ratio to one of five treatment groups:
Randomization will be stratified by extent of psoriasis (≥ 3% body surface area [BSA] or \< 3% BSA), current use of at least 1 non-biologic DMARD, presence of dactylitis, and presence of enthesitis, except for participants from China and Japan, where randomization for each country will be stratified by extent of psoriasis (≥ 3% BSA or \< 3% BSA) only.
Participants who complete the Week 56 visit (end of Period 1) will enter the long-term extension portion of the study, Period 2 (total treatment up to approximately 5 years), and continue study treatment as assigned in Period 1 in a blinded manner until the last subject completes the last visit of Period 1 (Week 56), when study drug assignment in both periods will be unblinded and participants will be dispensed study drug in an open-label fashion until the completion of Period 2.
At Week 16, rescue therapy will be offered to participants classified as non-responders (defined as not achieving at least 20% improvement in tender joint count (TJC) and / or swollen joint count (SJC) at both Week 12 and Week 16). Starting at Week 36, participants who fail to demonstrate at least 20% improvement in either or both TJC and SJC compared to Baseline at 2 consecutive visits will be discontinued from study drug treatment. Additionally, in participants continuing on study drug, starting at the Week 36 visit, initiation of or change in background PsA medication(s) is allowed as per local label.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of either at Screening:
Participant who is on current treatment with concomitant non-biologic DMARDs at study entry must be on \<= 2 non-biologic DMARDs (except the combination of MTX and leflunomide). The following non-biologic DMARDs are allowed: MTX, sulfasalazine, leflunomide, apremilast, hydroxychloroquine (HCQ) , bucillamine or iguratimod, and have been ongoing for >= 12 weeks and at stable dose for >= 4 weeks prior to the Baseline Visit. No other DMARDs are permitted during the study.
i. Participants who need to discontinue DMARDs prior to the Baseline Visit to comply with this inclusion criterion must follow the procedure specified below or at least five times the mean terminal elimination half-life of a drug:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants receive upadacitinib 15 mg orally once a day (QD) and matching placebo to adalimumab by subcutaneous injection every other week (EOW) for 56 weeks. Period 2: Participants will continue to receive upadacitinib 15 mg once daily.
Drug: Upadacitinib · Drug: Placebo to Adalimumab
Period 1: Participants receive upadacitinib 30 mg orally once a day and matching placebo to adalimumab by subcutaneous injection every other week for 56 weeks. Period 2: Participants will continue to receive upadacitinib 30 mg once daily.
Drug: Upadacitinib · Drug: Placebo to Adalimumab
Period 1: Participants receive adalimumab 40 mg by subcutaneous injection every other week and matching placebo to upadacitinib orally QD for 56 weeks. Period 2: Participants continue to receive adalimumab 40 mg every other week.
Drug: Adalimumab · Drug: Placebo to Upadacitinib
Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 15 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks. Period 2: Participants will continue to receive upadacitinib 15 mg once daily.
Drug: Upadacitinib · Drug: Placebo to Upadacitinib · Drug: Placebo to Adalimumab
Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 30 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks. Period 2: Participants will continue to receive upadacitinib 30 mg once daily.
Drug: Upadacitinib · Drug: Placebo to Upadacitinib · Drug: Placebo to Adalimumab
Administered by subcutaneous injection
Also known as: Humira®
Oral tablet
Also known as: ABT 494, RINVOQ®
Oral tablet
Administered by subcutaneous injection
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline and Week 12
Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16
The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).
Time frame: Baseline and Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.
Time frame: Baseline and Week 16
Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24
The Sharp-van der Heijde modified scoring method for PsA measures the level of joint damage from radiographs of the hands and feet, and was assessed by 2 independent, blinded readers. Joint erosion severity was assessed in 20 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 320 (worst). Joint space narrowing (JSN) was assessed in 20 joints of each hand and wrist, and 6 joints of each foot, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 208 (worst). Joints with gross osteolysis or pencil in cup were assigned the maximum score for both erosions and JSN. The total mTSS score is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 528 (worst). A negative change from Baseline indicates improvement in joint damage.
Time frame: Baseline and Week 24
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
Time frame: Week 24
Percentage of Participants With Resolution of Enthesitis at Week 24
Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst).
Time frame: Week 24
Percentage of Participants With an ACR20 Response at Week 12 - Non-inferiority Versus Adalimumab
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.
Time frame: Baseline and Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
Time frame: Baseline and Week 12
Percentage of Participants With an ACR20 Response at Week 12 - Superiority Versus Adalimumab
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With Resolution of Dactylitis at Week 24
Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. The Leeds Dactylitis Index (LDI) is a score based on finger circumference and tenderness, assessed and summed across all dactylitic digits (fingers and toes). The presence of a dactylitic digit is defined as at least one affected AND tender digit with circumference increase over reference digit ≥ 10%. The reference digit circumference is either the contralateral digit (unaffected digit on opposite hand or foot) if available, or from a standard reference table if otherwise. Tenderness of affected digits is assessed on a scale from 0 \[none\] to 3 \[worst\]. The ratio of circumference between an affected digit and reference digit is multiplied by the tenderness score for each affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.
Time frame: Week 24
Change From Baseline in Patient's Assessment of Pain - Superiority Versus Adalimumab
Participants were asked to indicate the severity of their arthritis pain within the previous week on a numerical rating scale (NRS) from 0 to 10. A score of 0 indicates "no pain" and a score of 10 indicates "worst possible pain." A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in HAQ-DI - Superiority Versus Adalimumab
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16
The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.
Time frame: Baseline and Week 16
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 2
This study was conducted at 282 sites in 44 countries and was initiated in April 2017. Adults with active psoriatic arthritis (PsA) and a history of inadequate response or intolerance to at least one non-biologic disease modifying anti-rheumatic drug (DMARD) were eligible for enrollment.
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | Adalimumab 40 mg Period 2 (Weeks 56 to 260) | Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Upadacitinib 30 mg Period 2 (Weeks 56 to 260) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 211 | 212 | 429 | 430 | 423 | 0 | 0 | 0 | 0 | 0 |
| Completed | 177 | 178 | 370 | 379 | 366 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 34 | 34 | 59 | 51 | 57 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 7 | 11 | 9 | 21 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 20 | 29 | 24 | 24 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 1 | 4 | 8 | 7 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 6 | 3 | 8 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 2 | 3 | 7 | 6 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive study drug | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | Adalimumab 40 mg Period 2 (Weeks 56 to 260) | Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Upadacitinib 30 mg Period 2 (Weeks 56 to 260) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 177 | 178 | 366 | 378 | 365 |
| Completed | 0 | 0 | 0 | 0 | 0 | 131 | 121 | 268 | 272 | 269 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 46 | 57 | 98 | 106 | 96 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 14 | 17 | 14 | 28 | 28 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 11 | 21 | 45 | 44 | 32 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 7 | 6 | 12 | 12 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 9 | 6 | 7 |
| Withdrew: Coviid-19 infection | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 3 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 0 | 0 | 10 | 7 | 17 | 12 | 18 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 36.2 (31.6 to 40.7) | 65.0 (60.5 to 69.5) | 70.6 (66.3 to 74.9) | 78.5 (74.6 to 82.4) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
| units on a scale | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | -0.14 (-0.18 to -0.09) | -0.34 (-0.38 to -0.29) | -0.42 (-0.47 to -0.37) | -0.47 (-0.52 to -0.42) |
The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | 10.9 (7.4 to 14.3) | 38.5 (33.2 to 43.7) | 41.9 (36.5 to 47.3) | 54.0 (48.6 to 59.4) |
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | 21.3 (15.8 to 26.9) | 53.1 (46.3 to 59.8) | 62.6 (56.1 to 69.1) | 62.4 (55.8 to 68.9) |
The Sharp-van der Heijde modified scoring method for PsA measures the level of joint damage from radiographs of the hands and feet, and was assessed by 2 independent, blinded readers. Joint erosion severity was assessed in 20 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 320 (worst). Joint space narrowing (JSN) was assessed in 20 joints of each hand and wrist, and 6 joints of each foot, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 208 (worst). Joints with gross osteolysis or pencil in cup were assigned the maximum score for both erosions and JSN. The total mTSS score is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 528 (worst). A negative change from Baseline indicates improvement in joint damage.
| score on a scale | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24 | 0.25 (0.13 to 0.36) | 0.01 (-0.11 to 0.13) | -0.04 (-0.16 to 0.07) | 0.03 (-0.08 to 0.15) |
A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24 | 12.3 (9.2 to 15.4) | 33.3 (28.9 to 37.8) | 36.6 (32.0 to 41.2) | 45.4 (40.6 to 50.1) |
Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Resolution of Enthesitis at Week 24 | 32.4 (26.5 to 38.3) | 47.2 (41.2 to 53.2) | 53.7 (47.8 to 59.7) | 57.7 (51.8 to 63.6) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an ACR20 Response at Week 12 - Non-inferiority Versus Adalimumab | 36.2 (31.6 to 40.7) | 65.0 (60.5 to 69.5) | 70.6 (66.3 to 74.9) | 78.5 (74.6 to 82.4) |
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.
| score on a scale | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 | 3.19 (2.41 to 3.96) | 6.82 (6.07 to 7.58) | 7.86 (7.09 to 8.63) | 8.90 (8.13 to 9.68) |
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
| score on a scale | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12 | 2.8 (1.9 to 3.7) | 5.7 (4.8 to 6.6) | 6.3 (5.4 to 7.2) | 7.1 (6.2 to 8.0) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an ACR20 Response at Week 12 - Superiority Versus Adalimumab | 36.2 (31.6 to 40.7) | 65.0 (60.5 to 69.5) | 70.6 (66.3 to 74.9) | 78.5 (74.6 to 82.4) |
Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. The Leeds Dactylitis Index (LDI) is a score based on finger circumference and tenderness, assessed and summed across all dactylitic digits (fingers and toes). The presence of a dactylitic digit is defined as at least one affected AND tender digit with circumference increase over reference digit ≥ 10%. The reference digit circumference is either the contralateral digit (unaffected digit on opposite hand or foot) if available, or from a standard reference table if otherwise. Tenderness of affected digits is assessed on a scale from 0 \[none\] to 3 \[worst\]. The ratio of circumference between an affected digit and reference digit is multiplied by the tenderness score for each affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Resolution of Dactylitis at Week 24 | 39.7 (31.1 to 48.2) | 74.0 (66.4 to 81.6) | 76.5 (69.3 to 83.6) | 79.5 (72.5 to 86.5) |
Participants were asked to indicate the severity of their arthritis pain within the previous week on a numerical rating scale (NRS) from 0 to 10. A score of 0 indicates "no pain" and a score of 10 indicates "worst possible pain." A negative change from Baseline indicates improvement.
| units on a scale | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in Patient's Assessment of Pain - Superiority Versus Adalimumab | -0.9 (-1.2 to -0.7) | -2.3 (-2.5 to -2.1) | -2.3 (-2.5 to -2.0) | -2.7 (-2.9 to -2.5) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
| score on a scale | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in HAQ-DI - Superiority Versus Adalimumab | -0.14 (-0.18 to -0.09) | -0.34 (-0.38 to -0.29) | -0.42 (-0.47 to -0.37) | -0.47 (-0.52 to -0.42) |
The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.
| score on a scale | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16 | -8.2 (-10.2 to -6.3) | -22.7 (-24.7 to -20.8) | -25.3 (-27.3 to -23.4) | -28.1 (-30.0 to -26.1) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 13.2 (10.0 to 16.5) | 37.5 (32.9 to 42.1) | 37.5 (32.9 to 42.1) | 51.8 (47.0 to 56.5) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 2.4 (0.9 to 3.8) | 13.8 (10.5 to 17.0) | 15.6 (12.2 to 19.1) | 25.3 (21.2 to 29.4) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2 | 12.1 (9.0 to 15.2) | 30.3 (26.0 to 34.7) | 28.2 (23.9 to 32.5) | 38.3 (33.7 to 42.9) |
Collected over All-cause mortality and adverse event tables include events reported from time informed consent was signed to end of the study. Median time on follow-up in Period 1 (days): Upa 15 mg (415); Upa 30 mg (414); Ada 40 mg (194); Pbo up to Wk 24 (418); Pbo/Upa 15 mg Wk 24-56 (419); and Pbo/Upa 30 mg Wk 24-56 (776.5). Median time on follow-up in Period 2 (days): Upa 15 mg (1458); Upa 30 mg (796.5); Ada 40 mg (1486); Pbo/Upa 15 mg (1459); Pbo/Upa 30 mg (790.5); and Upa 30 mg/Upa 15 mg (842).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Upadacitinib 15 mg Period 1 (Weeks 1 to 56) | 3/430 (0.7%) | 28/430 (6.5%) | 247/430 (57.4%) |
| Upadacitinib 30 mg Period 1 (Weeks 1 to 56) | 1/423 (0.2%) | 46/423 (10.9%) | 262/423 (61.9%) |
| Adalimumab 40 mg Period 1 (Weeks 1 to 56) | 1/429 (0.2%) | 35/429 (8.2%) | 220/429 (51.3%) |
| Placebo Period 1 (Weeks 1 to 24) | 1/423 (0.2%) | 13/423 (3.1%) | 150/423 (35.5%) |
| Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56) | 0/188 (0%) | 10/188 (5.3%) | 61/188 (32.4%) |
| Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56) | 0/190 (0%) | 11/190 (5.8%) | 76/190 (40%) |
| Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | 14/378 (3.7%) | 109/378 (28.8%) | 277/378 (73.3%) |
| Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | 8/366 (2.2%) | 66/366 (18%) | 218/366 (59.6%) |
| Adalimumab 40 mg Period 2 (Weeks 56 to 260) | 4/366 (1.1%) | 73/366 (19.9%) | 246/366 (67.2%) |
| Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | 3/177 (1.7%) | 34/177 (19.2%) | 130/177 (73.4%) |
| Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | 3/178 (1.7%) | 25/178 (14%) | 114/178 (64%) |
| Upadacitinib 30 mg / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | 6/443 (1.4%) | 55/443 (12.4%) | 271/443 (61.2%) |
| Event | Upadacitinib 15 mg Period 1 (Weeks 1 to 56) | Upadacitinib 30 mg Period 1 (Weeks 1 to 56) | Adalimumab 40 mg Period 1 (Weeks 1 to 56) | Placebo Period 1 (Weeks 1 to 24) | Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56) | Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56) | Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | Adalimumab 40 mg Period 2 (Weeks 56 to 260) | Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | Upadacitinib 30 mg / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 PNEUMONIAInfections and infestations | 0/430 | 0/423 | 0/429 | 0/423 | 0/188 | 0/190 | 18/378 | 16/366 | 3/366 | 8/177 | 6/178 | 5/443 |
| COVID-19Infections and infestations | 0/430 | 0/423 | 0/429 | 0/423 | 0/188 | 0/190 | 8/378 | 8/366 | 4/366 | 1/177 | 1/178 | 4/443 |
| PNEUMONIAInfections and infestations | 2/430 | 4/423 | 1/429 | 2/423 | 0/188 | 1/190 | 7/378 | 2/366 | 1/366 | 1/177 | 1/178 | 0/443 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/430 | 2/423 | 3/429 | 0/423 | 0/188 | 1/190 | 5/378 | 3/366 | 5/366 | 1/177 | 1/178 | 5/443 |
| SUDDEN DEATHGeneral disorders | 0/430 | 0/423 | 0/429 | 0/423 | 0/188 | 0/190 | 2/378 | 0/366 | 0/366 | 2/177 | 0/178 | 0/443 |
| HERPES ZOSTERInfections and infestations | 1/430 | 1/423 | 0/429 | 0/423 | 0/188 | 1/190 | 1/378 | 4/366 | 0/366 | 0/177 | 0/178 | 0/443 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 1/430 | 1/423 | 0/429 | 0/423 | 0/188 | 0/190 | 3/378 | 4/366 | 1/366 | 0/177 | 1/178 | 0/443 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/430 | 0/423 | 1/429 | 0/423 | 0/188 | 0/190 | 4/378 | 1/366 | 3/366 | 0/177 | 0/178 | 0/443 |
| FOOT DEFORMITYMusculoskeletal and connective tissue disorders | 0/430 | 0/423 | 0/429 | 0/423 | 0/188 | 0/190 | 1/378 | 0/366 | 3/366 | 0/177 | 0/178 | 1/443 |
| MYOCARDIAL INFARCTIONCardiac disorders | 1/430 | 2/423 | 0/429 | 0/423 | 0/188 | 0/190 | 3/378 | 1/366 | 1/366 | 0/177 | 0/178 | 0/443 |
| Event | Upadacitinib 15 mg Period 1 (Weeks 1 to 56) | Upadacitinib 30 mg Period 1 (Weeks 1 to 56) | Adalimumab 40 mg Period 1 (Weeks 1 to 56) | Placebo Period 1 (Weeks 1 to 24) | Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56) | Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56) | Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | Adalimumab 40 mg Period 2 (Weeks 56 to 260) | Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | Upadacitinib 30 mg / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/430 | 0/423 | 0/429 | 0/423 | 1/188 | 1/190 | 132/378 | 51/366 | 106/366 | 57/177 | 29/178 | 117/443 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 67/430 | 72/423 | 53/429 | 34/423 | 13/188 | 11/190 | 56/378 | 40/366 | 42/366 | 25/177 | 15/178 | 49/443 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 52/430 | 67/423 | 31/429 | 6/423 | 11/188 | 15/190 | 43/378 | 33/366 | 21/366 | 22/177 | 25/178 | 39/443 |
| PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders | 14/430 | 21/423 | 20/429 | 13/423 | 2/188 | 5/190 | 42/378 | 20/366 | 33/366 | 15/177 | 10/178 | 33/443 |
| URINARY TRACT INFECTIONInfections and infestations | 26/430 | 30/423 | 18/429 | 10/423 | 4/188 | 9/190 | 41/378 | 21/366 | 26/366 | 15/177 | 12/178 | 25/443 |
| NASOPHARYNGITISInfections and infestations | 36/430 | 45/423 | 43/429 | 21/423 | 7/188 | 16/190 | 38/378 | 24/366 | 31/366 | 15/177 | 9/178 | 36/443 |
| HYPERTENSIONVascular disorders | 33/430 | 21/423 | 15/429 | 10/423 | 2/188 | 2/190 | 39/378 | 11/366 | 26/366 | 15/177 | 10/178 | 20/443 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 32/430 | 39/423 | 44/429 | 12/423 | 6/188 | 8/190 | 33/378 | 23/366 | 30/366 | 18/177 | 9/178 | 19/443 |
| LATENT TUBERCULOSISInfections and infestations | 1/430 | 1/423 | 1/429 | 2/423 | 0/188 | 0/190 | 22/378 | 4/366 | 19/366 | 17/177 | 8/178 | 5/443 |
| BRONCHITISInfections and infestations | 28/430 | 33/423 | 13/429 | 10/423 | 6/188 | 3/190 | 27/378 | 12/366 | 16/366 | 16/177 | 6/178 | 25/443 |
All randomized participants
| Age, Continuous(years) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 50.0 ± 12.25 | 50.8 ± 12.18 | 51.4 ± 12.04 | 51.6 ± 12.18 | 49.9 ± 12.41 | 50.8 ± 12.22 |
| Age, Customized(Participants) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| < 65 years | 185 | 182 | 362 | 368 | 371 | 1468 |
| 65 - < 75 years | 24 | 28 | 61 | 52 | 46 | 211 |
| ≥ 75 years | 2 | 2 | 6 | 10 | 6 | 26 |
| Sex: Female, Male(Participants) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| Female | 98 | 113 | 222 | 239 | 236 | 908 |
| Male | 113 | 99 | 207 | 191 | 187 | 797 |
| Ethnicity (NIH/OMB)(Participants) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 29 | 37 | 65 | 60 | 53 | 244 |
| Not Hispanic or Latino | 182 | 175 | 364 | 370 | 370 | 1461 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| White | 190 | 187 | 375 | 387 | 377 | 1516 |
| Black or African American | 2 | 1 | 2 | 1 | 3 | 9 |
| American Indian/Alaska Native | 1 | 1 | 2 | 0 | 2 | 6 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 2 | 0 | 1 | 4 |
| Asian | 16 | 21 | 41 | 37 | 34 | 149 |
| Multiple | 2 | 1 | 7 | 5 | 6 | 21 |
| Extent of Psoriasis(Participants) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| < 3% BSA | 108 | 104 | 218 | 215 | 213 | 858 |
| ≥ 3% BSA | 103 | 108 | 211 | 214 | 210 | 846 |
| Missing | 0 | 0 | 0 | 1 | 0 | 1 |
| Current Use of at Least 1 Non-Biologic DMARD(Participants) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| Yes | 174 | 173 | 346 | 353 | 345 | 1391 |
| No | 37 | 39 | 83 | 77 | 78 | 314 |
| Presence of Dactylitis(Participants) | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Adalimumab 40 mg | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|---|---|
| Yes | 65 | 61 | 127 | 136 | 127 | 516 |
| No | 146 | 151 | 302 | 293 | 296 | 1188 |
| Missing | 0 | 0 | 0 | 1 | 0 | 1 |
10 further baseline measures are reported on the registry.
Showing the first 100 of 345 sites across 46 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Apr 2017 to primary completion in Sep 2019, 28 months.
Results were first posted in Jan 2022, 2 years 3 months after primary completion. A results delay was requested in Aug 2020.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 28 months is close to that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib